Drug Trial Radar · NCT00856986
The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Mar 8, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
987
Actual
Start
Mar 2009
Primary completion
Apr 2010
Study completion Nov 2010
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Mar 6, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 84 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in Europe and North America. The aim of this clinical trial is to assess and compare the effect of insulin detemir in combination with liraglutide and metformin versus liraglutide and metformin in subjects with type 2 diabetes. Subjects will continue their own pre-trial metformin treatment during the trial.
Conditions
- Diabetes
- Diabetes Mellitus, Type 2
Interventions
liraglutideDrug
Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.
insulin detemirDrug
Insulin detemir subcutaneous (under the skin) injection once daily. Dose will be titrated (individually adjusted) based on fasting self-measured plasma glucose levels according to a pre-specified algorithm
metforminDrug
Metformin tablets, at least 1500 mg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26.Time frame: Week 0 (Randomisation), week 26
Locations
233 sites in 10 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Alexander City, Alabama
Novo Nordisk Investigational Site
Birmingham, Alabama
Novo Nordisk Investigational Site
Encino, California
Novo Nordisk Investigational Site
Fullerton, California
Novo Nordisk Investigational Site
Inglewood, California
Novo Nordisk Investigational Site
La Jolla, California
Novo Nordisk Investigational Site
Los Gatos, California
Novo Nordisk Investigational Site
Montclair, California
Novo Nordisk Investigational Site
Spring Valley, California
Novo Nordisk Investigational Site
Tustin, California
Novo Nordisk Investigational Site
Walnut Creek, California
Novo Nordisk Investigational Site
Waterbury, Connecticut
Novo Nordisk Investigational Site
Bradenton, Florida
Novo Nordisk Investigational Site
Clearwater, Florida
Novo Nordisk Investigational Site
Jupiter, Florida
Novo Nordisk Investigational Site
Miami, Florida
Novo Nordisk Investigational Site
Miami, Florida
Novo Nordisk Investigational Site
Miami, Florida
Novo Nordisk Investigational Site
Atlanta, Georgia
Novo Nordisk Investigational Site
Decatur, Georgia
Novo Nordisk Investigational Site
Roswell, Georgia
Novo Nordisk Investigational Site
Savannah, Georgia
Novo Nordisk Investigational Site
Chicago, Illinois
Novo Nordisk Investigational Site
Quincy, Illinois
Novo Nordisk Investigational Site
Chicago Heights, Indiana
Novo Nordisk Investigational Site
Louisville, Kentucky
Novo Nordisk Investigational Site
Madisonville, Kentucky
Novo Nordisk Investigational Site
Baltimore, Maryland
Novo Nordisk Investigational Site
Hyattsville, Maryland
Novo Nordisk Investigational Site
Rockville, Maryland
Novo Nordisk Investigational Site
Methuen, Massachusetts
Novo Nordisk Investigational Site
St Louis, Missouri
Novo Nordisk Investigational Site
New Hyde Park, New York
Novo Nordisk Investigational Site
Northport, New York
Novo Nordisk Investigational Site
Syracuse, New York
Novo Nordisk Investigational Site
The Bronx, New York
Novo Nordisk Investigational Site
Charlotte, North Carolina
Novo Nordisk Investigational Site
Durham, North Carolina
Novo Nordisk Investigational Site
Cincinnati, Ohio
Novo Nordisk Investigational Site
Cincinnati, Ohio
Showing 40 of 233 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.